Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Barclays analyst Etzer Darout initiates coverage on Janux Therapeutics (NASDAQ:JANX) with a Overweight rating and announces ...
Truist Securities analyst Asthika Goonewardene initiates coverage on Janux Therapeutics (NASDAQ:JANX) with a Buy rating and ...
Stifel analyst Bradley Canino reinstates Janux Therapeutics (NASDAQ:JANX) with a Buy and announces $45 price target.
Guggenheim analyst Brad Canino initiates coverage on Janux Therapeutics (NASDAQ:JANX) with a Buy rating and announces Price ...
Piper Sandler analyst Kelsey Goodwin initiates coverage on Janux Therapeutics (NASDAQ:JANX) with a Overweight rating and ann...
Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel...
PSMA-TRACIr designed to be combined with potentially best-in-treatment asset, JANX007, and provide CD28 co-stimulation to furth...
